for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MorphoSys AG

MORG.DE

Latest Trade

93.30EUR

Change

-0.28(-0.30%)

Volume

120,152

Today's Range

92.68

 - 

94.30

52 Week Range

65.25

 - 

146.30

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
93.58
Open
93.82
Volume
120,152
3M AVG Volume
3.88
Today's High
94.30
Today's Low
92.68
52 Week High
146.30
52 Week Low
65.25
Shares Out (MIL)
32.74
Market Cap (MIL)
3,088.38
Forward P/E
166.90
Dividend (Yield %)
--

Next Event

MorphoSys AG ASH Annual Meeting & Exposition

Latest Developments

More

Morphosys Reports Q3 Revenue Of EUR 22 Mln

Morphosys Says Based On Preliminary Unaudited Consolidated Results For First 9 Months 2020,Now Sees Group Rev In Range Of Eur 317 Mln to Eur 327 Mln

Morphosys Places Convertible Bonds Due 2025 For EUR 325 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MorphoSys AG

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.

Industry

Biotechnology & Drugs

Contact Info

Semmelweisstr. 7

82152

Germany

+49.89.899270

https://www.morphosys.de/

Executive Leadership

Marc Cluzel

Independent Chairman of the Supervisory Board

Jean-Paul Kress

Chief Executive Officer

Jens Holstein

Chief Financial Officer, Member of the Management Board

David Trexler

President - MorphoSys US Inc

Sarah Fakih

Vice President and Head of Corporate Communications and Investor Relations

Key Stats

1.94 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.3K
EPS (EUR)

2017

-2.410

2018

-1.790

2019

-3.260

2020(E)

0.418
Price To Earnings (TTM)
48.35
Price To Sales (TTM)
10.20
Price To Book (MRQ)
5.14
Price To Cash Flow (TTM)
43.30
Total Debt To Equity (MRQ)
7.72
LT Debt To Equity (MRQ)
7.19
Return on Investment (TTM)
7.55
Return on Equity (TTM)
6.67

Latest News

Latest News

BRIEF-Incyte And MorphoSys Announce The Validation Of The European Marketing Authorization Application For Tafasitamab

* INCYTE AND MORPHOSYS ANNOUNCE THE VALIDATION OF THE EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR TAFASITAMAB

BRIEF-Morphosys Reports Q1 Revenue 251.2 Mln EUR Versus 13.5 Mln EUR Year Ago

* Q1 REVENUE 251.2 MILLION EUR VERSUS 13.5 MILLION EUR YEAR AGO

BRIEF-Vivoryon Says Morphosys Has Not Exercised Exclusive Option

* MORPHOSYS HAS NOT EXERCISED EXCLUSIVE OPTION TO LICENSE VIVORYON'S SMALL MOLECULE QPCTL INHIBITORS IN IMMUNO-ONCOLOGY FIELD Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-I-Mab And Morphosys Announce First Patient Dosed In Phase 3 Clinical Trial Of Tj202/Mor202 In R/R Multiple Myeloma In Mainland China

* I-MAB AND MORPHOSYS ANNOUNCE FIRST PATIENT DOSED IN PHASE 3 CLINICAL TRIAL OF TJ202/MOR202 IN R/R MULTIPLE MYELOMA IN MAINLAND CHINA Source text for Eikon: Further company coverage:

MorphoSys says coronavirus impacting clinical studies and business

German pharmaceutical company MorphoSys on Monday said restrictions on social life, which were imposed to contain the spread of the coronavirus, are impacting some of its clinical trials.

BRIEF-Morphosys FY Revenue 71.8 Million EUR Versus 76.4 Million EUR Year Ago

* FY REVENUE 71.8 MILLION EUR VERSUS 76.4 MILLION EUR YEAR AGO

BRIEF-Morphosys Resolves Capital Increase To Implement Purchase Of ADSs By Incyte

* DGAP-NEWS: MORPHOSYS RESOLVES A CAPITAL INCREASE TO IMPLEMENT THE PURCHASE OF 3,629,764 AMERICAN DEPOSITARY SHARES BY INCYTE CORPORATION

BRIEF-Morphosys, Incyte Announce Antitrust Clearance Of Global Collaboration And License Agreement For Tafasitamab

* DGAP-NEWS: MORPHOSYS AND INCYTE ANNOUNCE ANTITRUST CLEARANCE OF GLOBAL COLLABORATION AND LICENSE AGREEMENT FOR TAFASITAMAB

BRIEF-MorphoSys Says FDA Accepts License Application For Tafasitamab And Lenalidomide

* FDA ACCEPTS MORPHOSYS' BIOLOGICS LICENSE APPLICATION (BLA) AND GRANTS PRIORITY REVIEW FOR TAFASITAMAB AND LENALIDOMIDE FOR THE TREATMENT OF RELAPSED/REFRACTORY DLBCL

Morphosys CFO says tafasitamab drug sales potential above $1 billion: magazine

German biotech company Morphosys' tafasitamab, the group's most advanced drug which is currently being tested, has sales potential of significantly more than $1 billion a year, its finance chief said in remarks to a magazine.

Chief scientist quits at Germany's Morphosys ahead of product launch

Morphosys' <MORG.DE> chief scientific officer will quit after 17 years with the group, the latest change at the top of the German biotech firm as it gears up for its first product launch.

Morphosys to boost size of tafasitamab drug trial on encouraging interim data

German biotech company Morphosys said more patients would be recruited for a study testing its most advanced drug against a common type of blood cancer, following an encouraging interim data readout.

Morphosys shares fall after dermatitis treatment flops

German biotech company Morphosys halted development of an experimental atopic dermatitis treatment that analysts had pinned hopes of blockbuster sales potential on, sending its shares down as much as 6.8% on Tuesday.

BRIEF-Morphosys Announces End Of Clinical Development Program Of MOR106 In Atopic Dermatitis

* ANNOUNCED END OF CLINICAL DEVELOPMENT PROGRAM OF MOR106 IN ATOPIC DERMATITIS

CORRECTED-BRIEF-Morphosys Confirms Higher 2019 Revenue Guidance

* Financial year 2019 guidance, updated in July, confirmed: revenues in range of 65 mln to 72 mln eur

BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study

* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

German biotech group Morphosys seeks European partner for debut drug

German biotech firm Morphosys is in talks with potential partners to bring its debut drug, a therapeutic antibody against leukaemia, to Europe.

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

BRIEF-Morphosys AG Reports Q1 Revenue Of 2.8 Million EUR

* Q1 REVENUE 2.8 MILLION EUR VERSUS 11.8 MILLION EUR YEAR AGO

BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients

* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up